BRCA1 and breast cancer: Moreover, patients with metastatic disease (n = 23) at presentation had a four-fold risk of carrying the BRCA1-3’UTR-variant compared to Stage I breast cancer patients (p = 0.018, OR 3.73, 95% CI 1.26-11.07).